Borstein Family Foundation
EIN 954716815 Private FoundationTotal Given 2016–2024
$23.9M
284 grants · $2.7M avg/year
based on 9 yrs of IRS 990-PF records on file
$1M+/yr
mid-tier
capacity
$25K
typical mid grants · $10K–$50K
grant size
82%
deep partner · 49/60 multi-year
repeat
$41.3M
Assets (2024)
60
Distinct Recipients
Focus Areas
Application Information
Accepts Unsolicited Proposals
No. Preselected Only
Contact Person
HARVARD BUSINESS SCHOOL
Phone
(310) 582-1991
Financial Trends
Giving Over Time
Total Assets Over Time
View financial data as table
| Year | Total Giving | Total Assets | Revenue | Grants |
|---|---|---|---|---|
| 2016 | $302K | $11.9M | $1.5M | 19 |
| 2017 | $372K | $14.2M | $1.0M | 18 |
| 2018 | $2.4M | $14.9M | $2.4M | 36 |
| 2019 | $748K | $20.4M | $2.9M | 25 |
| 2020 | $1.1M | $30.6M | $9.3M | 26 |
| 2021 | $993K | $36.5M | $966K | 27 |
| 2022 | $5.8M | $31.6M | $2.2M | 33 |
| 2023 | $5.5M | $36.0M | $1.1M | 48 |
| 2024 | $6.7M | $41.3M | $4.1M | 52 |
Grant Size Distribution
Based on 284 grants on record
Minimum
$1K
25th Pctl
$10K
Median
$25K
Average
$84K
75th Pctl
$50K
Maximum
$3.2M
Geographic Distribution
Officers & Directors
Grants Awarded (284 total)
| Purpose | ||||
|---|---|---|---|---|
| St John's Health Center Foundation | LOS Angeles, CA | $3,200,000 | DRS. RICK ESSNER AND KIM MARGOLIN: MELANOMA PROGRAM | 2022 |
| Saint Johns Health Center Foundation | LOS Angeles, CA | $2,400,000 | FOR GENERAL FUND | 2023 |
| Saint Johns Health Center Foundation | LOS Angeles, CA | $1,800,000 | FOR GENERAL FUND | 2024 |
| John Wayne Cancer Institute | Santa Monica, CA | $800,000 | ST. JOHNS MELANOMA CENTER | 2022 |
| Saint Johns Health Center Foundation | LOS Angeles, CA | $800,000 | ST. JOHNS MELANOMA CENTER | 2023 |
| Saint Johns Health Center Foundation | LOS Angeles, CA | $800,000 | ST. JOHNS MELANOMA CENTER | 2024 |
| The Michael J. Fox Foundation | New York, NY | $750,000 | FOR GENERAL FUND | 2024 |
| National Jewish Health | Denver, CO | $650,000 | PULMONARY HYPERTENSION RESEARCH PROGRAM CONCEPTS | 2024 |
| City of Hope | Duarte, CA | $500,000 | IMMUNOTHERAPY TARGETING CCR4 FOR T-CELL LYMPHOMA | 2018 |
| City of Hope | Duarte, CA | $450,000 | FOR GENERAL FUND | 2024 |
| City of Hope | Duarte, CA | $450,000 | FOR GENERAL FUND | 2024 |
| City of Hope | Duarte, CA | $400,000 | CAR T-CELL THERAPY FOR CNS LYMPHOMA | 2018 |
| Leukemia Lymphoma Society | LOS Angeles, CA | $330,000 | PREDICTING RISK AND INDIVIDUALIZING THERAPY FOR LYMPHOMA | 2020 |
| City of Hope | Duarte, CA | $300,000 | DR. BUDDE-IMMUNOTHERAPY TARGETING CD33 FOR ACUTE MYELOID LEUKEMIA (AML) | 2022 |
| City of Hope | Duarte, CA | $300,000 | DR. MARCUCCI-TARGETING THE ENERGY PRODUCTION OF LSC'S IN AML | 2022 |
| The Leukemia & Lymphoma Society | Rye Brook, NY | $280,000 | PREDICTING RISK AND INDIVIDUALIZING THERAPY FOR LYMPHOMA | 2023 |
| City of Hope | Duarte, CA | $200,000 | DR. WANG RESEARCH: CAR T-CELL THERAPY FOR CNS LYMPHOMA | 2021 |
| City of Hope | Duarte, CA | $200,000 | DR. BUDDE-IMMUNOTHERAPY TARGETING CD33 FOR AACUTE MYELOID LEUKEMIA (AML) & DR. MARCUCCI-TARGETING THE ENERGY... | 2023 |
| City of Hope | Duarte, CA | $200,000 | FOR GENERAL FUND | 2023 |
| City of Hope | Duarte, CA | $200,000 | FOR GENERAL FUND | 2023 |
| UC Berkeley - Alzheimer's Research | Berkeley, CA | $200,000 | DR. KAUFER - BLOOD-BRAIN BARRIER DYSFUNCTION AS A NOVEL MECHANISM OF AD | 2024 |
| City of Hope | Duarte, CA | $200,000 | IMMUNOTHERAPY RESEARCH | 2018 |
| Ronald McDonald House | LOS Angeles, CA | $187,500 | OPERATIONAL SUPPORT FOR WEST LOS ANGELES AND LOS ANGELES HOUSES | 2022 |
| City of Hope | Duarte, CA | $150,000 | DR BUDDE TARGETING CCR4 FOR T CELL LYMPHOMA | 2020 |
| City of Hope | LOS Angeles, CA | $150,000 | DR BUDDE TARGETING CCR4 FOR T CELL LYMPHOMA | 2019 |
Looking for more funders like Borstein Family Foundation? Open the free Texas funder database and search 178,000+ foundations by state, type, and giving size.
Want to compare open opportunities instead? Open the free Texas grant database for active grants from federal, state, foundation, and corporate funders.